Reig Jofre starts marketing of three new injectble products for hospitals
Developments correspond to generic products based on specialized pharmaceutical technologies.
Reig Jofre has started the commercialization of three new injectable products for hospitals, developed by the R&D team of the injectable and antibiotic plants that the company has in Barcelona and Toledo, respectively. These developments correspond to generic products based on specialized pharmaceutical technologies.
Bivalirrudine 250 mg (active ingredient, Bivalirrudin) is a lyophilized injectable anticoagulant, indicated in both adult patients who undergo a percutaneous coronary intervention, including patients with myocardial infarction, and in the treatment of adult patients with unstable angina who will be subjected to an urgent or early surgery.
Bivalirrudine has been co-developed by the R&D team of the Barcelona injectable plant in collaboration with AMBIOPHARM, the North American developer and manufacturer of the active ingredient. The product is being registered in 16 markets (US among them) and is already being marketed in Spain, Denmark, Sweden, the UK and Australia. In the coming months, it is expected to start marketing this injectable in other countries.
Palonosetron 5 mg (active ingredient, Palonosetron HCl) is an injectable antiemetic indicated for the prevention of acute nausea and vomiting associated with cancer chemotherapy in adults, adolescents and children over one month old.
Also, developed in the Barcelona injectable plant, Palonestron has been registered in six markets and is already being marketed in Spain, UK, Denmark and Sweden.
Cefepime 1 g (active ingredient, Cefepime-Arginine) is an injectable antibiotic belonging to cephalosporin group, indicated in the treatment of respiratory, urinary and gastric infections, among others, caused by bacteria. This injectable, developed by the R&D team of the Toledo penicillin plant, has been registered in Spain, where it is already marketed.
To market its developments, Reig Jofre has its own sales network in six European markets, and business relationships with 130 partners in 63 countries on five continents. The company confirms its firm commitment to internationalization, whose spearhead is the line of antibiotics and injectable products for hospitals, the latter strongly boosted in 2016 by the entry in Japan.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance